2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes …

F Cosentino, PJ Grant, V Aboyans… - European heart …, 2020 - academic.oup.com
Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association

J Rangaswami, V Bhalla, JEA Blair, TI Chang, S Costa… - Circulation, 2019 - Am Heart Assoc
Cardiorenal syndrome encompasses a spectrum of disorders involving both the heart and
kidneys in which acute or chronic dysfunction in 1 organ may induce acute or chronic …

Exploring the role of the patient–physician relationship on insulin adherence and clinical outcomes in type 2 diabetes: Insights from the MOSAIc study: 在2 型糖尿病 …

B Linetzky, D Jiang, MM Funnell, BH Curtis… - Journal of …, 2017 - Wiley Online Library
背景为期2 年的前瞻性MOSAIc (Multinational Observational Study assessing Insulin use:
understanding the challenges associated with progression of therapy, 评估胰岛素使用情况的 …

Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study …

MJ Davies, DA D'Alessio, J Fradkin, WN Kernan… - Diabetes …, 2018 - pmc.ncbi.nlm.nih.gov
Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the …

MJ Davies, DA D'Alessio, J Fradkin, WN Kernan… - Diabetologia, 2018 - Springer
Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …

Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study …

MJ Davies, VR Aroda, BS Collins, RA Gabbay… - Diabetes …, 2022 - Am Diabetes Assoc
The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the previous consensus statements on the management of …

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

R Pratley, A Amod, ST Hoff, T Kadowaki, I Lingvay… - The Lancet, 2019 - thelancet.com
Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective
treatments for type 2 diabetes, lowering glycated haemoglobin (HbA 1c) and weight, but are …

Metformin: historical overview

CJ Bailey - Diabetologia, 2017 - Springer
Metformin (dimethylbiguanide) has become the preferred first-line oral blood glucose-
lowering agent to manage type 2 diabetes. Its history is linked to Galega officinalis (also …

Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes …

MS Capehorn, AM Catarig, JK Furberg, A Janez… - Diabetes & …, 2020 - Elsevier
Aims SUSTAIN 10 compared the efficacy and safety of the anticipated most frequent
semaglutide dose (1.0 mg) with the current most frequently prescribed liraglutide dose in …

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the …

MJ Davies, VR Aroda, BS Collins, RA Gabbay, J Green… - Diabetologia, 2022 - Springer
Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the previous consensus statements on the …